Participated · Series B · Aug 2026

Vaderis is developing engasertib (VAD044), an investigational once-daily oral selective allosteric AKT1/2 inhibitor intended to treat hereditary hemorrhagic telangiectasia (HHT). The company has advanced engasertib into pivotal development following positive proof-of-concept and long-term extension data published in The New England Journal of Medicine. Vaderis has initiated HEROIC, a global Phase 3 randomized, double-blind, placebo-controlled study enrolling patients across North America, South America and Europe. The company intends to use proceeds from its $152 million Series B to support operations through regulatory submissions and potential U.S. approval. Vaderis is headquartered in Basel, Switzerland, with a U.S. subsidiary in Lincolnshire, Illinois. The company positions engasertib as a potential first approved therapy specifically developed for people living with HHT.

Led · Series D · Jul 2026

FORE Biotherapeutics is a registration-stage targeted oncology company whose lead asset is plixorafenib (FORE8394; formerly PLX8394), a BRAF inhibitor with a mechanism described as both a dimer and paradox breaker. The company is advancing plixorafenib in the global Phase 2 FORTE Master Protocol, a registration-intended basket study that includes monotherapy baskets for recurrent or progressive BRAF V600E primary CNS tumors, rare BRAF V600 mutated solid tumors, and advanced solid tumors with BRAF fusions. Fore reported that target enrollment of approximately 50 patients has been reached in the BRAF V600E CNS tumor basket and expects topline results from that basket around the end of 2026; the company anticipates a potential regulatory submission if the primary analysis is positive. Plixorafenib received Breakthrough Therapy Designation from the FDA in April 2026, and prior Phase 1/2 data showed a 67% ORR in MAPK inhibitor–naïve BRAF V600 primary recurrent CNS tumors (n=9) and a 42% response rate with a median duration of response of 17.8 months in V600-altered, MAPK inhibitor–naïve patients. The company reported a favorable safety profile for plixorafenib, including a drug-related discontinuation rate of less than 2%, and has implemented protocol changes in FORTE such as allowing dosing with food and lowering the minimum enrollment age to 8 years based on IDMC clearance.

Participated · Series B · Feb 2026

Altesa BioSciences is focused on treating chronic lung diseases by targeting the viral infections that trigger respiratory exacerbations. Its lead oral candidate, vapendavir, is designed to neutralise rhinovirus—the predominant cause of exacerbations in millions of COPD and asthma patients. In a recently completed Challenge Study, vapendavir improved upper and lower airway symptoms, shortened illness duration, lowered inflammatory markers, and preserved small-airway function relative to placebo. The company projects that, if approved, vapendavir could prevent up to 50 % of COPD exacerbations, improving quality of life and reducing healthcare costs. Altesa plans to launch the 900-patient Phase 2b CARDINAL study in the US and UK in Q2 2026 to further evaluate safety and efficacy. Led by former U.S. Assistant Secretary of Health Brett P. Giroir, M.D., and guided by a board chaired by Moncef Slaoui, Ph.D., the team includes seasoned executives with backgrounds at GSK and other major firms. The firm is headquartered in Atlanta and advocates for expanded access to modern respiratory diagnostics and therapeutics in underserved communities.

Participated · Series B · Dec 2025

D3 Bio focuses on discovering, developing, and registering innovative medicines that address key driver mutations and immune pathways in cancer. Its lead asset is elisrasib (D3S-001), a KRAS G12C inhibitor being advanced toward global Phase III pivotal trials as both a monotherapy and in combination regimens. The company’s broader pipeline spans targeted and immuno-oncology programs built on proprietary clinical insights and biomarker strategies, all of which it owns global rights to. The recent $108 million Series B financing underscores investor confidence in the firm’s scientific approach and global development capabilities. Proceeds will fund late-stage clinical development of elisrasib across the United States, China, and the European Union and support continued pipeline expansion. While specific revenue or patient enrollment figures were not disclosed, the successful raise highlights the company’s solid financial footing for its near-term clinical milestones.

Led · Series B · Mar 2025

Curevo is a clinical-stage biotechnology company focused on developing vaccines with improved tolerability and accessibility. Its lead product, amezosvatein, is a non-mRNA adjuvanted sub-unit vaccine designed to prevent shingles. The company raised $110M in a Series B to accelerate clinical development. Curevo intends to use the funds to extend its Phase 2 program by an additional 640 participants, including adults over age 70, to finalize dose selection ahead of Phase 3. Leadership includes CEO George Simeon, and the financing is accompanied by additions to the board to support late-stage development planning. The company is based in Seattle, WA. Curevo Vaccine is a Seattle-based, clinical-stage biotech focused on developing safe, highly effective subunit vaccines using an adjuvanted platform. Its lead candidate, CRV-101, is an adjuvanted subunit vaccine being evaluated to prevent shingles in older adults and was designed to use a smaller amount of adjuvant to aim for comparable efficacy with fewer side effects. In Phase 1, CRV-101 showed robust humoral and cellular immunogenicity with no grade 3 injection-site reactions and a 1.3% rate of grade 3 systemic side effects. CRV-101 is in a head-to-head Phase 2b trial versus Shingrix®, in which Curevo enrolled 678 patients in six months; topline data were expected in early 2023. The company is also developing a non-live subunit chickenpox vaccine. Financially, Curevo completed a $26 million Series A1 financing and previously raised $86 million in 2022, which company management says extends its cash runway. Curevo Vaccine is a clinical-stage biotech based in Seattle focused on developing safe, highly effective adjuvanted subunit vaccines via its sub-unit vaccine technology platform. Its lead product, CRV-101, is an adjuvanted sub-unit vaccine under investigation to prevent shingles in older adults and is designed to use less adjuvant to aim for similar efficacy with fewer side effects. The company reported encouraging Phase 1 data showing robust humoral and cellular immunogenicity, no grade 3 injection-site side effects, and a 1.3% rate of grade 3 systemic side effects. Curevo is conducting a 678-patient Phase 2b trial intended to compare CRV-101’s immunogenicity and safety profile relative to Shingrix. The firm is also developing a non-live subunit chickenpox vaccine to address unmet needs for more accessible vaccines. Curevo announced a $60 million Series A to fund clinical development through topline data from the Phase 2b trial.